Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday, marking the end of the Bluebird’s fall from the one of the buzziest biotec… [+3203 chars]Read More
Once highflying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker CNBC
